Metsera (NASDAQ:MTSR) Sets New 1-Year Low - Here's Why

Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s stock price hit a new 52-week low during trading on Wednesday . The stock traded as low as $22.29 and last traded at $22.43, with a volume of 150051 shares trading hands. The stock had previously closed at $24.51.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Evercore ISI initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating on the stock. Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price target on the stock. Guggenheim assumed coverage on Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating for the company.

Metsera Price Performance

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share (EPS) for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.